Role of SGLT2I in Patients With Myocardial Infarction

N/AUnknownNCT06245980

Dongying Zhang1,200 enrolled

Overview

Role of sglt2I in diabetic patients with myocardial infarction

Study Type

OBSERVATIONAL

Enrollment

1,200

Conditions

Myocardial Infarction Diabetes Mellitus

Interventions

SGLT2 inhibitorDRUG

According to whether SGLT2i was used

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Acute myocardial infarction patients 2. Type 2 diabetics. Exclusion Criteria: 1. Patients undergoing coronary artery bypass grafting (CABG). 2. Severe valvular heart disease. 3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins. 4. Previously used SGLT2i. 5. Severe hepatic and renal insufficiency.

Locations (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

MACE

cardiovascular death and heart failure and myocardial infarction

Time frame: 24months

Heart failure readmission

Time frame: 24months

Secondary Outcomes

Recurrent myocardial infarction

Time frame: 24months

cardiovascular death

Time frame: 24months

Central Contacts

xuesong wen

CONTACT

+8618702384027 1979272415@qq.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.